Clover Health VP Sells 20,000 Shares Amid Mixed Institutional Activity

Clover Health Investments, Corp. (NASDAQ:CLOV) disclosed that Vice President Joseph Frank Oldakowski sold 20,000 shares on September 14. The transaction, valued at $103,200 at an average price of $5.16, reduced his direct ownership by 6.69% to 279,067 shares. This follows a similar divestment in June, where the executive sold 12,102 shares at $4.86, signaling a pattern of reducing personal equity exposure despite the company's recent market performance.

The stock traded up 5.8% to $5.10 on Monday, with volume reaching 5.4 million shares against an average of 3.4 million. According to data reported by GN stocks/nasdaq, Clover Health carries a market capitalization of $2.71 billion and a beta of 2.47. The shares currently trade above their 50-day moving average of $4.43 and significantly above the 200-day average of $3.55, reflecting a strong upward trend since the twelve-month low of $1.58.

Q2 Results Show Revenue Growth

Clover Health reported second-quarter results on August 5, delivering an EPS of $0.05, which exceeded the consensus estimate of $0.04. Revenue reached $743.17 million, surpassing analyst projections of $728.27 million. However, the company remains in the red, posting a negative net margin of 0.74% and a negative return on equity of 4.20%. The P/E ratio stands at -101.98, indicating that the business is not yet generating sufficient profit to justify its current valuation based on earnings alone.

Institutional Investors Adjust Holdings

Large institutional investors have significantly modified their stakes in the company. The California State Teachers Retirement System increased its position by 387.2% in Q2, adding 1.92 million shares to hold a total of 2.42 million shares worth approximately $12.69 million. Bank of New York Mellon Corp and Tidal Investments LLC also initiated new positions valued at $6.35 million and $2.16 million, respectively. Conversely, Turtle Creek Wealth Advisors increased its stake by 29.4% in Q1, while Lazard Asset Management entered the market with a $309,000 position.

Institutional ownership now accounts for 19.77% of the outstanding shares. These moves contrast with the internal selling by the vice president, suggesting a divergence in confidence between executive leadership and external fund managers. The recent accumulation by major retirement funds and asset managers indicates that despite the lack of profitability, these investors are betting on the company's future growth trajectory and market share expansion.

Analyst Ratings Remain Divided

Wall Street opinions on Clover Health remain split, with no consensus on the fair value. Canaccord Genuity raised its price target to $5.50 with a buy rating, while UBS Group maintains a neutral stance with a $5.00 target. In contrast, Weiss Ratings reiterates a sell rating, citing fundamental weaknesses. Deutsche Bank initiated coverage with a buy rating and a $6.00 target, the highest among recent notes. Currently, two analysts rate the stock as Buy, three as Hold, and one as Sell, reflecting the uncertainty surrounding the company's path to profitability.